Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN Expert Centres

Further Publications

Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 patients

Clin Cancer Res

Sato T, Butler MO, Piperno-Neumann S, Hassel JC, Nathan P, Shoushtari AN, Rutkowski P, Carvajal RD, Baurain JF, Schlaak M, Piulats JM, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, Ikeguchi A, Joshua AM, Middleton MR, Edukulla R, Pfeiffer C, Sacco JJ

doi: 10.1158/1078-0432.CCR-25-1513

Skin Cancer

Predictive value of [(18)F]FDG PET/CT and index lymph node response following neoadjuvant pembrolizumab in resectable stage 3 melanoma: Real world data from the largest melanoma centres in the Netherlands

Eur J Cancer

Wilson MJ, Schurink AW, Schrage Y, Wouters MWJM, van Houdt WJ, Grunhagen DJ, van Thienen HV, van de Wiel BA, van der Hiel B, Kuijpers AMJ

doi: 10.1016/j.ejca.2026.116691

Further Publications

Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma

Ann Oncol

Piperno-Neumann S, Rutkowski P, Hassel JC, Butler MO, Schlaak M, Sullivan RJ, Dummer R, Kirkwood JM, Sacco JJ, Shoushtari AN, Piulats JM, Salama AKS, Orloff MM, Joshua AM, Ochsenreither S, Gastaud L, Curti BD, Demidov LV, Milhem MM, Chmielowski B, Kendra KL, Ascierto PA, Bernicker EH, Carvajal RD, Collins L, Lockwood S, Patel JM, Hamid OA, Baurain JF, Nathan PD

doi: 10.1016/j.annonc.2026.05.695

Skin Cancer

Health-Related Quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared to ipilimumab in a randomized phase 3 trial

Ann Oncol

Ten Ham RMT, Rohaan MW, Egeler M, Menezes R, Holz Borch T, Kessels R, Jedema I, Nuijen B, Nijenhuis C, van de Poll-Franse LV, Geukes Foppen MH, Lindenberg M, Mansfield Noringriis I, Monberg TJ, Donia M, van Harten W, Svane IM, Haanen JBAG, Retèl VP

doi: 10.1016/j.annonc.2025.06.005

Skin Cancer

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study

Eur J Cancer

Albrecht LJ, Garnier J, Zaremba A, Brauch L, Brunnert F, Rauschenberg R, Forschner A, Vazquez XG, Mangana J, Erdmann M, Angela Y, Franklin C, Tietze J, Lodde G, Tasdogan A, Seier JA, Roesch A, Ugurel S, Berking C, Gutzmer R, Heinzerling L, Meier F, Mohr P, Hassel JC, Schadendorf D, Livingstone E, Zimmer L

doi: 10.1016/j.ejca.2026.116595

Breast Cancer

Molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): using real-world data to describe this unique clinical entity

Clin Cancer Res

Davis AA, Jaeger E, Hagemann IS, Behdad A, Layng KV, Gerratana L, Mauer E, Shah AN, D'Amico P, Flaum L, Reduzzi C, Navo K, Gradishar WJ, Ahmed T, Chao C, Cristofanilli M

doi: 10.1158/1078-0432.CCR-25-0359

Leukemia

Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL - real-life data analysis of the Polish Adult leukemia group

Leuk Lymphoma

Zielonka K, Izdebski B, Drozd-Sokołowska J, Pruszczyk-Matusiak K, Puła B, Wiśniewski K, Sawicki W, Kalicińska E, Jabłonowska-Babij P, Butrym A, Buczek T, Subocz E, Hałka J, Witkowska M, Wilk M, Hryniewiecka M, Gruenpeter K, Cichocka E, Halicki P, Wdowiak K, Iskierka-Jażdżewska E, Kopińska A, Szlauer-Stefańska A, Szymczyk A, Wolska-Washer A, Kowalczyk J, Wróbel T, Hus I, Jamroziak K

doi: 10.1080/10428194.2025.2535693

Gastrointestinal Cancer

Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF-PARAGON study)

Int J Cancer

Goetze TO, Al-Batran SE, Liersch R, Scheuer L, Goehler T, Kaiser U, Denzlinger C, Brandl S, Pink D, Uhlig J, Maasberg M, Loose M, Schaaf M, Sookthai D, Zäpf B, Pauligk C, Habibzade T, Hofheinz RD, Koch C, AIO Study Group

doi: 10.1002/ijc.70280

SABCS 2025

Breast Cancer

Related content

Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 patients

Predictive value of [(18)F]FDG PET/CT and index lymph node response following neoadjuvant pembrolizumab in resectable stage 3 melanoma: Real world data from the largest melanoma centres in the Netherlands

Five-Year Survival with Tebentafusp in Metastatic Uveal Melanoma

Health-Related Quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared to ipilimumab in a randomized phase 3 trial

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study

Molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): using real-world data to describe this unique clinical entity

Venetoclax and obinutuzumab in first-line treatment of unfit patients with CLL - real-life data analysis of the Polish Adult leukemia group

Treatment landscape from first- to third-line therapy and quality of life data of patients with pancreatic cancer from the prospective German PARAGON (Platform for Outcome, Quality of Life, and Translational Research on Pancreatic Cancer) registry (IKF-PARAGON study)

Sacituzumab govitecan shows clinically meaningful activity in real-world patients with metastatic TNBC and intracranial disease